AHA/ASA guideline recommendations for prevention of stroke in women atrial fibrillation: Difference between revisions
Line 29: | Line 29: | ||
| colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] | | colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] | ||
|- | |- | ||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki> | |bgcolor="LemonChiffon"|<nowiki>"</nowiki> Antiplatelet therapy is a reasonable therapeutic option for selected low-risk women aged ≤65 years with AF alone (no other risk factors; women with CHADS2=0 or CHA2DS2-VASc=1). ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki> | ||
|} | |} | ||
Revision as of 16:44, 11 February 2014
Stroke Main page | |
Diagnosis | |
---|---|
Treatment | |
Case Studies | |
AHA/ASA guideline recommendations for prevention of stroke in women atrial fibrillation On the Web | |
American Roentgen Ray Society Images of AHA/ASA guideline recommendations for prevention of stroke in women atrial fibrillation | |
FDA on AHA/ASA guideline recommendations for prevention of stroke in women atrial fibrillation | |
CDC on AHA/ASA guideline recommendations for prevention of stroke in women atrial fibrillation | |
AHA/ASA guideline recommendations for prevention of stroke in women atrial fibrillation in the news | |
Blogs on AHA/ASA guideline recommendations for prevention of stroke in women atrial fibrillation | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ayokunle Olubaniyi, M.B,B.S [2]
Overview
2014 AHA/ASA Guideline Recommendations for Prevention of Stroke in Women (DO NOT EDIT)
Class I |
"1. Risk stratification tools in AF that account for age and sex-specific differences in the incidence of stroke are recommended. (Level of Evidence: A) " |
"2. Considering the increased prevalence of AF with age and the higher risk of stroke in elderly women with AF, active screening (in particular of women >75 years of age) in primary care settings using pulse taking followed by an ECG as appropriate is recommended. (Level of Evidence: B) " |
"3. New oral anticoagulants are a useful alternative to warfarin for the prevention of stroke and systemic thromboembolism in women with paroxysmal or permanent AF and prespecified risk factors (according to CHA2DS2-VASc) who do not have a prosthetic heart valve or hemodynamically significant valve disease, severe renal failure (creatinine clearance 15 mL/min), lower weight (<50 kg), or advanced liver disease (impaired baseline clotting function). (Level of Evidence: A) " |
Class III (No Benefit) |
" Oral anticoagulation in women aged ≤65 years with AF alone (no other risk factors; women with CHADS2=0 or CHA2DS2-VASc=1) is not recommended (Level of Evidence: B) " |
Class IIa |
" Antiplatelet therapy is a reasonable therapeutic option for selected low-risk women aged ≤65 years with AF alone (no other risk factors; women with CHADS2=0 or CHA2DS2-VASc=1). (Level of Evidence: B) " |